Tuesday, 12 March 2013

EpiCast Report: Postmenopausal Vaginal Atrophy Available on Researchmoz.us

ResearchMoz.us include new market research report"EpiCast Report: Postmenopausal Vaginal Atrophy - Epidemiology Forecast to 2022 " to its huge collection of research reports.

Postmenopausal Vaginal Atrophy

The urogenital tract, specifically the vagina, urethra, bladder, trigone of the bladder, and pelvic floor muscles, contains estrogen receptors. Estrogen is needed for the health of these tissues and structures, a lack of which causes them to undergo atrophy (Castelo-Branco and Rostro, 2007; Nappi and Kokot-Kierepa, 2012). During the menopause transition and postmenopausal periods, women can experience a number of symptoms primarily due to estrogen depletion that include vasomotor and urogenital symptoms. Although vasomotor symptoms typically resolve over time, urogenital symptoms remain a persistent consequence of estrogen depletion (Winneker and Harris, 2011). Postmenopausal vaginal atrophy (PVA) is the term used to describe the group of urogenital symptoms that arise due to estrogen depletion and is also known as urogenital atrophy, vulvovaginal atrophy, and atrophic vaginitis (Mac Bride et al., 2010; Willhite and O’Connell, 2001). Approximately 10%–50% of postmenopausal women experience symptoms of vaginal atrophy, but only about 25% of them seek medical treatment (NAMS, 2007; Nappi and Kokot-Kierepa, 2012).
Cultural and social attitudes toward sexuality and aging are the primary determinants of the extent to which women report symptoms associated with PVA; therefore, the amount of PVA epidemiology data available in a given country varies considerably (Barlow et al., 1997). Today, women are living longer and spend approximately one third of their lives in the postmenopausal state. For this reason, there is evidence that in some regions, such as North America, attitudes towards the menopause transition are changing, and women are becoming more vocal about their menopause experience (Wright, 1998). Any changes in cultural and social norms that decrease the stigma surrounding menopause will likely lead to an increase in the diagnosed prevalence of PVA over time. The increase could exceed the projections of PVA prevalence found in this analysis.
Buy a copy of this report: http://www.researchmoz.us/epicast-report-postmenopausal-vaginal-atrophy-epidemiology-forecast-to-2022-report.html


The Postmenopausal Vaginal Atrophy EpiCast Report and EpiCast Model provide an overview of the risk factors and global trends of postmenopausal vaginal atrophy in the seven major markets (the US, France, Germany, Italy, Spain, the UK, and Japan). It includes a 10-year epidemiology forecast of PVA prevalent cases segmented by age (in five-year increments beginning at 50 years and ending at 79 years) and severity (mild, moderate, and severe) in the 7MM.

Reasons To Buy

Develop business strategies by understanding the trends shaping and driving the global postmenopausal vaginal atrophy market.Quantify patient populations in the global postmenopausal vaginal atrophy market to improve product design, pricing, and launch plans.Organize sales and marketing efforts by identifying the age groups and severity levels that present the best opportunities for postmenopausal vaginal atrophy therapeutics in each of the markets covered.Identify the percentage of postmenopausal vaginal atrophy cases that are mild, moderate, and severe

To Read The Complete Report with TOC Kindly Visit: http://www.researchmoz.us/epicast-report-postmenopausal-vaginal-atrophy-epidemiology-forecast-to-2022-report.html

For More Information Kindly Contact
Email: sales@researchmoz.us
Blog: http://researchmoz.blogspot.com